Acadia Healthcare (NASDAQ:ACHC) and Biocorrx (OTCMKTS:BICX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.
This is a breakdown of current recommendations for Acadia Healthcare and Biocorrx, as reported by MarketBeat.
||Strong Buy Ratings
Acadia Healthcare presently has a consensus price target of $41.70, indicating a potential upside of 30.27%. Given Acadia Healthcare’s higher possible upside, research analysts clearly believe Acadia Healthcare is more favorable than Biocorrx.
Volatility and Risk
Acadia Healthcare has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
Institutional and Insider Ownership
0.0% of Biocorrx shares are held by institutional investors. 11.1% of Acadia Healthcare shares are held by company insiders. Comparatively, 14.9% of Biocorrx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Acadia Healthcare and Biocorrx’s gross revenue, earnings per share and valuation.
||Earnings Per Share
Acadia Healthcare has higher revenue and earnings than Biocorrx.
This table compares Acadia Healthcare and Biocorrx’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Acadia Healthcare beats Biocorrx on 7 of the 11 factors compared between the two stocks.
About Acadia Healthcare
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities. The company operates acute inpatient psychiatric facilities, which offer evaluation and crisis stabilization of patients with severe psychiatric diagnoses; specialty treatment facilities, including residential recovery facilities, eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders; and residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. It also provides outpatient community-based services, such as community-based programs that are designed to offer therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric, or chemical dependency disorder. In addition, the company provides mental health services; rehabilitation services comprising relapse prevention and social integration services, as well as vocational opportunities; acute services for patients at risk to themselves or others, as well as crisis intervention and treatment of behavioral emergencies; and long-term and non-acute care services for adults suffering from mental illness, addiction, learning disability, or brain injury. Further, it provides education and children's services for children and young people with special educational needs; adult and elderly care services; and care first services for employees. As of December 31, 2017, the company operated a network of 582 behavioral healthcare facilities with approximately 17,800 beds in the United States, the United Kingdom, and Puerto Rico. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. The company distributes and licenses BioCorRx recovery program, a medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant. It is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is headquartered in Anaheim, California.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.